Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New agents for Gram-positive bacteria.

S M Bhavnani1, C H Ballow

  • 1Clinical Pharmacokinetics Laboratory, Kaleida Health/Millard Fillmore Hospital and School of Pharmacy, State University of New York-Buffalo, NY, USA.

Current Opinion in Microbiology
|October 26, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide.

Antimicrobial agents and chemotherapy·2023
Same author

Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.

Antimicrobial agents and chemotherapy·2023
Same author

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics.

Antimicrobial agents and chemotherapy·2023
Same author

Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber <i>In Vitro</i> Infection Model.

Antimicrobial agents and chemotherapy·2023
Same author

Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia.

Antimicrobial agents and chemotherapy·2022
Same author

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.

Antimicrobial agents and chemotherapy·2022
Same journal

A conceptual framework to dissect emergent functions in microbial communities.

Current opinion in microbiology·2026
Same journal

Differential signaling roles of the KinA-KinE sensor kinases in regulating Spo0A, the master regulator of Bacillus subtilis cell‑fate decisions.

Current opinion in microbiology·2026
Same journal

S-layers as natural building blocks for nanobiotechnology and synthetic biology.

Current opinion in microbiology·2026
Same journal

The role of the antimicrobial peptide nisin as a clean label food preservative.

Current opinion in microbiology·2026
Same journal

From coarse-grained metabolic rules to fine-grained control of microbial communities.

Current opinion in microbiology·2026
Same journal

Progress in engineered bacterial cancer therapies.

Current opinion in microbiology·2026
See all related articles

Two novel antimicrobial agents, quinupristin/dalfopristin and linezolid, offer new hope against dangerous multi-resistant Gram-positive infections. New fluoroquinolones also provide options for treating resistant Streptococcus pneumoniae infections.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Multiple-resistant Gram-positive organisms pose a significant and growing global health threat.
  • Existing treatments are becoming less effective due to widespread antimicrobial resistance.

Purpose of the Study:

  • To highlight the emergence and importance of new antimicrobial agents for combating resistant Gram-positive infections.
  • To introduce quinupristin/dalfopristin and linezolid as novel therapeutic options.
  • To discuss the role of new fluoroquinolones in treating infections caused by resistant Streptococcus pneumoniae.

Main Methods:

  • Review of recently approved antimicrobial agents.
  • Analysis of their specific targets and applications.
  • Discussion of their potential impact on clinical practice.

Related Experiment Videos

Main Results:

  • Quinupristin/dalfopristin and linezolid have been approved in the USA for treating life-threatening infections.
  • These agents are specifically designed to target multi-resistant Gram-positive organisms.
  • New fluoroquinolones are becoming available to address resistant Streptococcus pneumoniae strains.

Conclusions:

  • The introduction of quinupristin/dalfopristin and linezolid represents a significant advancement in managing difficult-to-treat Gram-positive infections.
  • These new drugs, along with emerging fluoroquinolones, are expected to play a crucial role in combating antimicrobial resistance worldwide.